Scientists uncover protein that helps cancer cells dodge CAR T-cell therapy

LA fires update: Salgia home is standing

Last week, The Cancer Letter interviewed City of Hope physician Ravi Salgia, who evacuated from his Eaton Canyon home with his wife on the evening of Jan. 7 due to approaching wildfires driven by the Santa Ana winds.

January 17, 2025

Vol.51 No.02

In Brief

John Fryer joins TGen as professor, director of Center for Accelerated Nanotherapeutics

The Translational Genomics Research Institute, part of City of Hope, has announced the appointment of John D. Fryer as a professor in the Division of Bioinnovation and Genome Sciences and director of the newly established Center for Accelerated Nanotherapeutics.

January 17, 2025

Vol.51 No.02

As fire encroached, City of Hope prepared to evacuate its Duarte campus

On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest.

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Researchers from City of Hope, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and NIH have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor T-cell therapy resistance. The new system is outlined in a paper published in Nature Biomedical Engineering.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Nektar Therapeutics announced results of its phase II proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma at the 66th ASH Annual Meeting and Exposition in San Diego.

December 13, 2024

Vol.50 No.46

Clinical Roundup

CAR T-cell therapy obe-cel demonstrates high response rates in advanced B-cell ALL

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia who were treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy, obecabtagene autoleucel, experienced high response rates and most did not need a subsequent stem cell transplant, according to results from the phase Ib/II FELIX trial co-led by researchers at the University of Texas MD Anderson Cancer Center.

December 06, 2024

Vol.50 No.45

Scientists uncover protein that helps cancer cells dodge CAR T-cell therapy

YOU MAY BE INTERESTED IN

LA fires update: Salgia home is standing

John Fryer joins TGen as professor, director of Center for Accelerated Nanotherapeutics

As fire encroached, City of Hope prepared to evacuate its Duarte campus

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

CAR T-cell therapy obe-cel demonstrates high response rates in advanced B-cell ALL

Renew today!

Subscriber content

Never miss an issue!

Login